ARDELYX
Ardelyx develops novel, first-in-class oral therapeutics to correct mineral metabolism and metabolic disorders. The Company's molecules, whose systemic exposure is severely restricted, target transporters and receptors, modulating the uptake of nutrients or inducing secretion of key hormones to produce a therapeutic benefit in patients. The Company's non-systemic products act from within the intestines to avoid potential side effects that could occur with systemic exposure. The Company's lead pr... oduct, RDX5791, a minimally-absorbed, orally administered NHE3 sodium transport inhibitor, is being developed both for constipation-predominant irritable bowel syndrome (IBS-C) and for prevention of excess dietary sodium absorption, a new treatment modality for high blood pressure. RDX5791 is in phase 2 for IBS-C and a dose-ranging/regimen study for inhibition of excess dietary sodium absorption. Ardelyx is also developing RDX002, a minimally-absorbed, orally administered NaP2b phosphate transport inhibitor for the inhibition of phosphate absorption in patients with chronic kidney disease, and RDX009, a minimally-absorbed, orally administered TGR5 agonist for the treatment of type 2 diabetes through direct induction of intestinal incretins such as GLP-1 and PYY. Both RDX002 and RDX009 are in preclinical development. To date, Ardelyx has raised $56M in venture and angel funding since it was founded in 2007. Ardelyx is located in Fremont, California.
ARDELYX
Industry:
Biotechnology Health Care Medical
Founded:
2007-01-01
Address:
Fremont, California, United States
Country:
United States
Website Url:
http://www.ardelyx.com
Total Employee:
101+
Status:
Active
Contact:
510) 745-1700
Email Addresses:
[email protected]
Total Funding:
346.38 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon WordPress Google Universal Analytics
Similar Organizations
C4 Therapeutics
C4 Therapeutics develops novel early stage therapies that eliminate disease-causing proteins.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
HebeCell
HebeCell develops and commercializes cell-based therapeutics to treat incurable diseases.
Neumora Therapeutics
Neumora Therapeutics operates as a clinical-stage biotechnology company.
Praxis Precision Medicines
Praxis Precision Medicines offers drug development services.
Viking Therapeutics
Viking Therapeutics is developing novel therapeutics for patients suffering from metabolic and endocrine disorders.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Kyowa Kirin
Kyowa Kirin investment in Post-IPO Debt - Ardelyx
HealthCare Royalty Partners
HealthCare Royalty Partners investment in Post-IPO Debt - Ardelyx
SLR Capital Partners
SLR Capital Partners investment in Post-IPO Debt - Ardelyx
Cormorant Asset Management
Cormorant Asset Management investment in Post-IPO Equity - Ardelyx
Quadrille Capital
Quadrille Capital investment in Post-IPO Equity - Ardelyx
New Enterprise Associates
New Enterprise Associates investment in Post-IPO Equity - Ardelyx
RA Capital Management
RA Capital Management investment in Post-IPO Equity - Ardelyx
Deerfield
Deerfield investment in Post-IPO Equity - Ardelyx
Dafna Capital Management
Dafna Capital Management investment in Post-IPO Equity - Ardelyx
EcoR1 Capital
EcoR1 Capital investment in Post-IPO Equity - Ardelyx
Key Employee Changes
Official Site Inspections
http://www.ardelyx.com Semrush global rank: 2.28 M Semrush visits lastest month: 8.27 K
- Host name: 141.193.213.10
- IP address: 141.193.213.10
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago